UNSPSC 51393204: Meluadrine tartrate

This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C12H18ClNO2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6P0KL436YB, chemically known as benzenemethanol, 2-chloro-.alpha.-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (.alpha.r)-, (2r,3r)-2,3-dihydroxybutanedioate (1:1) (salt), but more generally known as meluadrine tartrate, which bears US NIH Compound Identifier 636384.

European Medicines Agency schedules meluadrine tartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08730MIG. Most nations, for tariff purposes, schedule meluadrine tartrate under HS 29225000. SMILES: CC(C)(C)NC[C@@H](C1CCC(CC1CL)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51393204 Meluadrine tartrate is a Commodity code with minimal recent state and local procurement activity directly aligned to the product name. The two recent opportunities tagged to this code—a Seminole County, Florida IFB for naloxone and drug deactivation systems and a Texas Health and Human Services Commission RFI for direct-to-manufacturer prescription programs—diverge significantly from meluadrine tartrate itself. The Seminole County solicitation targets naloxone (an opioid antagonist used in overdose response) and drug deactivation systems through competitive bidding, while the Texas HHS RFI explores pharmacy benefit management and direct manufacturer contracting models for prescription fulfillment. Neither opportunity directly solicits meluadrine tartrate or reflects active state and local demand for this specific pharmaceutical product. The issuing bodies span county health agencies and state health and human services commissions, but the recent record shows no pattern of repeat procurement under this code.

The geographic activity reflected in these opportunities is limited to Florida and Texas, with no evidence of broader state or regional concentration. Seminole County's IFB (posted June 30, 2026, due July 26, 2023—note the date discrepancy in the source) targets annual procurement of naloxone and deactivation systems with quarterly deliveries and a two-year initial term plus one-year renewal option, while the Texas HHS RFI (posted April 3, 2026) represents exploratory market intelligence gathering rather than a committed procurement. The code shows little relevant recent activity aligned to meluadrine tartrate as a distinct pharmaceutical commodity at the state and local level. Business development professionals should monitor whether future solicitations under this code will address the nominal product or continue to reflect misalignment between the UNSPSC designation and actual purchasing intent.